BIOMAT Database Logo BIOMAT Database Logo

Genetic alterations on chromosome 17 in human breast cancer: relationships to clinical features and DNA ploidy. 1993

M Watatani, and K Nagayama, and Y Imanishi, and K Kurooka, and T Wada, and H Inui, and K Hirai, and M Ozaki, and M Yasutomi
First Department of Surgery, Kinki University School of Medicine, Osaka-Sayama, Japan.

We analyzed DNA from 105 primary breast cancers to assess amplification of the ERBB2 gene and loss of heterozygosity (LOH) on chromosome 17 using 4 polymorphic markers, and investigated the relationships of these genetic alterations to clinicopathological characteristics including DNA ploidy. Amplification of the ERBB2 gene was observed in 28% of the tumors. ERBB2 was amplified in tumors of all clinical stages and amplification was significantly linked to lymph node metastasis. LOH at D17S5 was observed in 28 of 57 informative tumors, while 17 of 62 informative tumors showed allelic loss at TP53. Among the 37 tumors informative for both loci, 32% showed LOH at these loci and 49% retained both alleles, indicating that there was a significant relationship between LOH at D17S5 and at TP53. We also examined LOH at the D17S74 and NME1 loci on chromosome 17q. LOH at D17S74 and NME1 was observed in 20% and 22% of the informative tumors, respectively, but there was no significant association between LOH at these loci. Of the 4 loci tested, LOH at TP53, D17S74, and NME1 was associated with clinical stage. Lymph node metastasis was correlated with LOH at NME1. Moreover, allelic loss was more frequent in aneuploid tumors than in diploid tumors. These results suggest that certain combinations of genetic alterations on chromosome 17 may cooperate in the development and/or progression of breast cancer. Furthermore, it seems likely that analysis of these alterations in breast cancer patients may provide useful prognostic information.

UI MeSH Term Description Entries
D011003 Ploidies The degree of replication of the chromosome set in the karyotype. Ploidy
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D002872 Chromosome Deletion Actual loss of portion of a chromosome. Monosomy, Partial,Partial Monosomy,Deletion, Chromosome,Deletions, Chromosome,Monosomies, Partial,Partial Monosomies
D002886 Chromosomes, Human, Pair 17 A specific pair of GROUP E CHROMOSOMES of the human chromosome classification. Chromosome 17
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D005260 Female Females
D005784 Gene Amplification A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication. Amplification, Gene

Related Publications

M Watatani, and K Nagayama, and Y Imanishi, and K Kurooka, and T Wada, and H Inui, and K Hirai, and M Ozaki, and M Yasutomi
HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study.
August 2019, Scientific reports,
M Watatani, and K Nagayama, and Y Imanishi, and K Kurooka, and T Wada, and H Inui, and K Hirai, and M Ozaki, and M Yasutomi
Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer.
March 1995, British journal of cancer,
M Watatani, and K Nagayama, and Y Imanishi, and K Kurooka, and T Wada, and H Inui, and K Hirai, and M Ozaki, and M Yasutomi
Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.
October 2011, Human pathology,
M Watatani, and K Nagayama, and Y Imanishi, and K Kurooka, and T Wada, and H Inui, and K Hirai, and M Ozaki, and M Yasutomi
Genetic alterations of chromosome 17 in human breast carcinoma studied by fluorescence in situ hybridization and molecular DNA techniques.
July 1994, Cancer genetics and cytogenetics,
M Watatani, and K Nagayama, and Y Imanishi, and K Kurooka, and T Wada, and H Inui, and K Hirai, and M Ozaki, and M Yasutomi
DNA ploidy of human breast cancer.
August 1989, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology,
M Watatani, and K Nagayama, and Y Imanishi, and K Kurooka, and T Wada, and H Inui, and K Hirai, and M Ozaki, and M Yasutomi
HER-2, TOP2A and chromosome 17 alterations in breast cancer.
January 2007, Pathology oncology research : POR,
M Watatani, and K Nagayama, and Y Imanishi, and K Kurooka, and T Wada, and H Inui, and K Hirai, and M Ozaki, and M Yasutomi
Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer.
March 1993, Diagnostic molecular pathology : the American journal of surgical pathology, part B,
M Watatani, and K Nagayama, and Y Imanishi, and K Kurooka, and T Wada, and H Inui, and K Hirai, and M Ozaki, and M Yasutomi
[Genetic alterations in the region of the p53 gene on human chromosome 17 in colorectal cancer].
August 1998, Genetika,
M Watatani, and K Nagayama, and Y Imanishi, and K Kurooka, and T Wada, and H Inui, and K Hirai, and M Ozaki, and M Yasutomi
Genetic alterations of microsatellites on chromosome 18 in human breast carcinoma.
March 1995, Diagnostic molecular pathology : the American journal of surgical pathology, part B,
M Watatani, and K Nagayama, and Y Imanishi, and K Kurooka, and T Wada, and H Inui, and K Hirai, and M Ozaki, and M Yasutomi
Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes.
December 2013, Breast (Edinburgh, Scotland),
Copied contents to your clipboard!